By Amy Friedrich-Karnik, Director, Public Policy |
Jul 27, 2018
Together with 52 patient advocacy groups, we submitted a response to the U.S. Department of Health & Human Services (HHS) RFI on its Blueprint to Lower Drug Prices & Reduce OOP Costs on July 16, 2018. Our patients are our priority, and we want to be sure their needs are considered in future policy development.